If your email program has trouble displaying this email, view as a webpage.

FDA Office of Minority Health and Health Equity

March 15, 2023

Coronavirus (COVID-19) Update: FDA Authorizes Bivalent Pfizer-BioNTech COVID-19 Vaccine as Booster Dose for Certain Children 6 Months through 4 Years of Age

Today, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine, Bivalent to provide for a single booster dose of the vaccine in children 6 months through 4 years of age at least 2 months after completion of primary vaccination with three doses of the monovalent (single strain) Pfizer-BioNTech COVID-19 Vaccine.

Visit the FDA OMHHE website and follow us on Twitter at @FDAHealthEquity 
"Creating a world where health equity is a reality for all."
www.fda.gov/HealthEquity